- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Asia Pacific Active Pharmaceutical Ingredients Market – Size, Outlook, Trends and Forecast (2024 – 2032)
The Active Pharmaceutical Ingredient (API) is the element of any drug that produces its effects. Few drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. The quality of APIs has a significant effect on the efficacy and safety of medications. Poorly manufactured or compromised APIs have been connected to severe issues, such as illnesses and even death.
Asia-Pacific Active Pharmaceutical Ingredients Market Segments Size & Growth:
Asia-Pacific active pharmaceutical ingredients market size is projected to reach approximately $78 billion by the end of 2024 with a CAGR of close to 8.6% from $45 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rising Prevalence of Cancer, Increasing Adoption of Biologicals and Biosimilars and Huge Impact on Pharmaceutical Industry. However, Drug Price Control Policies across Various Countries, Fierce Competition between the Active Pharmaceutical Ingredients(API)(API) Manufacturers and Stringent Regulations are thereby hampering the market growth.
Asia-Pacific Active Pharmaceutical Ingredients Market Segments Share:
The Asia-pacific active pharmaceutical market is categorised into a Business model which comprises of Merchant Active Pharmaceutical Ingredients (API) and Captive Active Pharmaceutical Ingredients (API). Among them, Captive active pharmaceutical ingredients(API) holds the most significant segment and merchant APIs are expected to be the fastest growing segment over the forecast period. By the Customer base, the market is segmented into generic and branded. Among them, Generic holds the most significant share over the forecast period. By application, the market is segmented into cardiology, pulmonology, Oncology, and so on. Among them, Cardiology segment is expected to hold the most significant share over the forecast period due to various growth factors. By Geography, India and China are projected to dominate the market with the most significant share and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Active Pharmaceutical Ingredients Market Trends:
- The Bristol-Myers Squibb-Pfizer Alliance includes an analysis of the progress made by 20 countries in implementing stroke prevention policies. One finding was that efforts to screen people for stroke risk factors, including AFib and hypertension, remain low, even in countries with established health care and developed economies.
- GSK welcomes the launch of the Government’s Life Sciences Sector Deal, which builds on the Industrial Strategy published by Sir John Bell earlier in the year, by announcing £40million of new money to strengthen initiatives that harness advances in genetic research in the development of new medicines.
Asia-Pacific Active Pharmaceutical Ingredients Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Teva Active Pharmaceutical Industries Limited
- Ranbaxy Laboratories
- Pfizer, Inc
- Novartis
- Mylan N.V
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Cancer
4.1.2 Increasing Adoption of Biologicals and Biosimilars
4.1.3 Huge Impact from Pharmaceutical Industry
4.2 Restraints
4.2.1 Fierce Competition between the Active Pharmaceutical Ingredients (API) (API) Manufacturers
4.2.2 Drug Price Control Policies across Various Countries
4.2.3 Stringent Regulations
4.3 Opportunities
4.3.1 Emerging Technologies
4.3.2 Emerging Markets
4.3.3 Increasing Scope for High-Potency Active Pharmaceutical Ingredients
4.3.4 Emerging Biosimilars Market
4.4 Challenges
4.4.1 High Manufacturing Costs
4.4.2 Product Differentiation
5. Asia-Pacific Active Pharmaceutical Ingredients Market – By Business Mode
5.1 Captive Active Pharmaceutical Ingredients (API)
5.2 Merchant Active Pharmaceutical Ingredients (API)
6. Asia-Pacific Active Pharmaceutical Ingredients Market-By Type of Synthesis
6.1 Synthetic
6.2 Biotech
7. Asia-Pacific Active Pharmaceutical Ingredients Market-By Customer Base
7.1 Generic
7.2 Branded
8. Asia-Pacific Active Pharmaceutical Ingredients Market – By Application
8.1 Cardiology
8.2 Pulmonology
8.3 Oncology
8.4 Ophthalmology
8.5 Neurology
8.6 Orthopedics
9. Asia-Pacific Active Pharmaceutical Ingredients Market – By Country
9.1.Introduction
9.2. India
9.3.China
9.4. Japan
9.5 Rest of Asia-Pacific
10. Company Profiles
10.1 Shandong Lukang Pharmaceutical
10.2 Albemarle
10.3 Lupin
10.4 Tian Yao
10.5 Cipla
10.6 Haerbin Pharmaceutical Group
10.7 Huahai Pharmaceutical
10.8 Lonza group
10.9 Shandong Xinhua Pharmaceutical
10.10 Cambrex
10.11 Hisun Pharmacy
10.12 Biocon
10.13 Zhejiang Medicine
10.14 Aurobindo pharma
10.15 Dr. Reddy’s Laboratories
11. Asia-Pacific Active Pharmaceutical Ingredients Market – Competitive Landscape
11.1 Market Share Analysis
11.2 Strategies Adopted by top companies
11.3 Mergers, Acquisitions, Collaborations & Agreements
12. Market Insights
12.1 Insights of Industry Experts
12.2 Investment Opportunities
12.3 Analyst Opinion
13. Appendix
13.1 List of Tables
13.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Regional Report
$2,160.00 – $7,200.00
- EUR: €2,003.90 - €6,679.65
- INR: ₹180,387.75 - ₹601,292.51
- AED: د.إ7,927.20 - د.إ26,424.00
- GBP: £1,724.45 - £5,748.18
Description
Regional Reports
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
The Active Pharmaceutical Ingredient (API) is the element of any drug that produces its effects. Few drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. The quality of APIs has a significant effect on the efficacy and safety of medications. Poorly manufactured or compromised APIs have been connected to severe issues, such as illnesses and even death.
Asia-Pacific Active Pharmaceutical Ingredients Market Segments Size & Growth:
Asia-Pacific active pharmaceutical ingredients market size is projected to reach approximately $78 billion by the end of 2024 with a CAGR of close to 8.6% from $45 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Rising Prevalence of Cancer, Increasing Adoption of Biologicals and Biosimilars and Huge Impact on Pharmaceutical Industry. However, Drug Price Control Policies across Various Countries, Fierce Competition between the Active Pharmaceutical Ingredients(API)(API) Manufacturers and Stringent Regulations are thereby hampering the market growth.
Asia-Pacific Active Pharmaceutical Ingredients Market Segments Share:
The Asia-pacific active pharmaceutical market is categorised into a Business model which comprises of Merchant Active Pharmaceutical Ingredients (API) and Captive Active Pharmaceutical Ingredients (API). Among them, Captive active pharmaceutical ingredients(API) holds the most significant segment and merchant APIs are expected to be the fastest growing segment over the forecast period. By the Customer base, the market is segmented into generic and branded. Among them, Generic holds the most significant share over the forecast period. By application, the market is segmented into cardiology, pulmonology, Oncology, and so on. Among them, Cardiology segment is expected to hold the most significant share over the forecast period due to various growth factors. By Geography, India and China are projected to dominate the market with the most significant share and the growth in the Asia-Pacific economies is mainly attributed because of huge profit margins and growth prospects.
Asia-Pacific Active Pharmaceutical Ingredients Market Trends:
- The Bristol-Myers Squibb-Pfizer Alliance includes an analysis of the progress made by 20 countries in implementing stroke prevention policies. One finding was that efforts to screen people for stroke risk factors, including AFib and hypertension, remain low, even in countries with established health care and developed economies.
- GSK welcomes the launch of the Government’s Life Sciences Sector Deal, which builds on the Industrial Strategy published by Sir John Bell earlier in the year, by announcing £40million of new money to strengthen initiatives that harness advances in genetic research in the development of new medicines.
Asia-Pacific Active Pharmaceutical Ingredients Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- Teva Active Pharmaceutical Industries Limited
- Ranbaxy Laboratories
- Pfizer, Inc
- Novartis
- Mylan N.V
1.Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Rising Prevalence of Cancer
4.1.2 Increasing Adoption of Biologicals and Biosimilars
4.1.3 Huge Impact from Pharmaceutical Industry
4.2 Restraints
4.2.1 Fierce Competition between the Active Pharmaceutical Ingredients (API) (API) Manufacturers
4.2.2 Drug Price Control Policies across Various Countries
4.2.3 Stringent Regulations
4.3 Opportunities
4.3.1 Emerging Technologies
4.3.2 Emerging Markets
4.3.3 Increasing Scope for High-Potency Active Pharmaceutical Ingredients
4.3.4 Emerging Biosimilars Market
4.4 Challenges
4.4.1 High Manufacturing Costs
4.4.2 Product Differentiation
5. Asia-Pacific Active Pharmaceutical Ingredients Market – By Business Mode
5.1 Captive Active Pharmaceutical Ingredients (API)
5.2 Merchant Active Pharmaceutical Ingredients (API)
6. Asia-Pacific Active Pharmaceutical Ingredients Market-By Type of Synthesis
6.1 Synthetic
6.2 Biotech
7. Asia-Pacific Active Pharmaceutical Ingredients Market-By Customer Base
7.1 Generic
7.2 Branded
8. Asia-Pacific Active Pharmaceutical Ingredients Market – By Application
8.1 Cardiology
8.2 Pulmonology
8.3 Oncology
8.4 Ophthalmology
8.5 Neurology
8.6 Orthopedics
9. Asia-Pacific Active Pharmaceutical Ingredients Market – By Country
9.1.Introduction
9.2. India
9.3.China
9.4. Japan
9.5 Rest of Asia-Pacific
10. Company Profiles
10.1 Shandong Lukang Pharmaceutical
10.2 Albemarle
10.3 Lupin
10.4 Tian Yao
10.5 Cipla
10.6 Haerbin Pharmaceutical Group
10.7 Huahai Pharmaceutical
10.8 Lonza group
10.9 Shandong Xinhua Pharmaceutical
10.10 Cambrex
10.11 Hisun Pharmacy
10.12 Biocon
10.13 Zhejiang Medicine
10.14 Aurobindo pharma
10.15 Dr. Reddy’s Laboratories
11. Asia-Pacific Active Pharmaceutical Ingredients Market – Competitive Landscape
11.1 Market Share Analysis
11.2 Strategies Adopted by top companies
11.3 Mergers, Acquisitions, Collaborations & Agreements
12. Market Insights
12.1 Insights of Industry Experts
12.2 Investment Opportunities
12.3 Analyst Opinion
13. Appendix
13.1 List of Tables
13.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.